Global Cardiac Arrest Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Product (Value) (Devices, Defibrillators, Extracorporeal Membrane Oxygenation (ECMO), Intra-aortic Balloon Pump (IABP), Percutaneous VAD (Impella), Other Devices, Drugs, Anti-arrhythmic Drugs, Class I – Sodium-channel Blockers, Class II – Beta-blockers, Class III – Potassium-channel Blockers, Class IV – Calcium-channel Blockers|||, Others (Digoxin, Adenosine), Vasopressors & Inotropes), By End User (Value) (Hospitals & Cardiac Centres, Emergency Medical Services (EMS), Home & Alternate Care Settings), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2020 - 2031
Market Size (2025)	USD 5.23 Billion
CAGR (2026-2031)	4.45%
Fastest Growing Segment	Asia Pacific
Largest Market	North America
Market Size (2031)	USD 6.79 Billion

Market Overview

The Global Cardiac Arrest Treatment Market is expected to grow from USD 5.23 Billion in 2025 to USD 6.79 Billion by 2031 at a 4.45% CAGR. The global cardiac arrest treatment market encompasses medical devices, pharmaceuticals, and interventional procedures aimed at resuscitating individuals experiencing sudden cardiac arrest and managing post-resuscitation care. Main drivers supporting this market's expansion include the escalating global prevalence of cardiovascular diseases, an aging demographic increasingly susceptible to cardiac events, growing public awareness regarding the critical importance of early defibrillation and cardiopulmonary resuscitation, and continuous innovation in resuscitation techniques and guidelines.

According to the European Resuscitation Council Guidelines 2025, the annual incidence of emergency medical services-treated out-of-hospital cardiac arrest in Europe is approximately 55 per 100,000 inhabitants, with an overall survival rate of roughly 7.5%. A significant challenge that could impede market expansion is the considerable variability in access to immediate, high-quality emergency medical services and advanced cardiac life support across diverse geographical regions, especially within developing economies.

Key Market Drivers

Rising CVD Burden Drives Demand for Cardiac Arrest Therapies
The increasing prevalence of cardiovascular diseases (CVDs) remains a primary catalyst for the global cardiac arrest treatment market's expansion, as these conditions are direct precursors to cardiac arrest. As global populations face a rising burden of heart-related ailments, the demand for effective resuscitation therapies and post-resuscitation care escalates. According to the European Society of Cardiology's 2025 Atlas project report, published in May 2026, cardiovascular diseases accounted for more than 3 million deaths annually across its member countries. This substantial mortality figure underscores the critical need for advanced cardiac arrest interventions and highlights the direct correlation between CVD incidence and market demand, driving the development and adoption of new treatment modalities.

Resuscitation Innovations and Preparedness Drive Market Growth
Concurrently, continuous technological advancements in resuscitation devices and techniques are instrumental in shaping the market landscape. Innovations in automated external defibrillators, mechanical cardiopulmonary resuscitation devices, and extracorporeal membrane oxygenation systems improve patient outcomes and expand the scope of treatable cardiac arrest cases. According to Stryker's operating results for the fourth quarter and full year of 2025, published in January 2026, the company reported an 11.4% increase in net sales to $7.2 billion. This strong financial performance from a leading medical technology company reflects ongoing investment and success in the development of such crucial medical devices. Furthermore, efforts to enhance public preparedness also significantly influence market growth. According to the American Heart Association, in September 2026, the organization was on track to implement over 1,000 Cardiac Emergency Response Plans during the year. These initiatives contribute to greater adoption and utilization of treatment solutions.

Download Free Sample Report

Key Market Challenges

Geographic Variability in EMS Access Impedes Market Growth
A significant impediment to the global cardiac arrest treatment market's expansion is the substantial variability in access to immediate, high-quality emergency medical services and advanced cardiac life support across diverse geographical regions, particularly within developing economies. This inconsistency directly hampers market growth by limiting the effective reach and utilization of critical medical devices, pharmaceuticals, and interventional procedures. Where emergency medical services are inadequately resourced or unevenly distributed, many individuals experiencing sudden cardiac arrest do not receive timely or effective resuscitation, leading to considerably lower survival rates. This outcome reduces the overall pool of patients requiring subsequent advanced care, such as post-resuscitation management devices or specialized medications for organ support.

US EMS Infrastructure Variability Constrains Market Penetration
According to the 2025 American Heart Association Guidelines, the incidence of emergency medical services-treated out-of-hospital cardiac arrest in the United States was 378.7 individuals per 100,000 population, with significant variation in both incidence and survival between states. This demonstrates how disparities in emergency care infrastructure, even in a developed nation, directly translate into lost opportunities for treatment and subsequent market demand for cardiac arrest-related products and services. Consequently, manufacturers face considerable challenges in achieving broader market penetration in regions where foundational emergency healthcare systems are underdeveloped, thus restraining overall market potential.

Key Market Trends

Connected resuscitation ecosystems: real-time data sharing and coordinated response
The integration of connected resuscitation ecosystems represents a significant trend, enhancing real-time data sharing and coordinated response during cardiac arrest events. This involves networked medical devices, electronic health records, and communication platforms working in concert to streamline care from initial emergency contact through post-resuscitation management. Such systems improve diagnostic accuracy, facilitate prompt treatment protocols, and allow for continuous patient monitoring, thereby optimizing the chain of survival. According to Philips' Q4 and full-year 2025 results, published in February 2026, its Connected Care business segment, which includes emergency care solutions, delivered comparable sales growth of 7% in the fourth quarter of 2025. This growth reflects the increasing adoption of integrated technologies that enable more efficient and effective emergency medical interventions.

Wearable and predictive cardiac monitoring expansion
Another pivotal trend shaping the global cardiac arrest treatment market is the expansion of wearable and predictive cardiac monitoring solutions. These technologies empower individuals with proactive health management by detecting subtle physiological changes that may precede a cardiac event, allowing for earlier intervention and risk mitigation. Wearable devices, often coupled with AI-powered analytics, provide continuous heart rhythm monitoring and can alert both users and healthcare providers to potential anomalies. The proliferation of these solutions contributes to a shift towards preventative and pre-hospital care, potentially reducing the incidence and severity of out-of-hospital cardiac arrests. AliveCor, a prominent provider of personal electrocardiogram technology, reported in an August 2026 press release that its Kardia devices have recorded over 350 million ECGs, highlighting the extensive use and growing reliance on these personal monitoring tools. This widespread adoption underscores the market's trajectory towards innovative, patient-centric approaches for cardiac risk management.

Segmental Insights

Drivers of Asia Pacific Cardiac Arrest Treatment Market Growth
The Asia Pacific region is rapidly emerging as the fastest-growing segment within the Global Cardiac Arrest Treatment Market. This accelerated expansion is primarily driven by a confluence of factors, including the escalating incidence of cardiovascular diseases and sudden cardiac arrest across the region, stemming from changing lifestyles and an increasing geriatric population. Furthermore, rising disposable incomes and corresponding increases in healthcare expenditure contribute significantly to market growth. Enhanced emergency-care funding in urban areas, coupled with the rising availability and adoption of automated external defibrillators (AEDs), including cost-effective options from domestic manufacturers adhering to International Electrotechnical Commission (IEC) standards, further propel this segment's robust development.

Regional Insights

North America Leads the Cardiac Arrest Treatment Market Through Advanced Infrastructure and Regulatory Support
North America stands as the leading region in the global cardiac arrest treatment market, primarily driven by its advanced healthcare infrastructure and a significant burden of cardiovascular diseases necessitating effective interventions. The region benefits from well-developed emergency medical services and widespread adoption of established treatment protocols, including automated external defibrillators and essential pharmaceuticals. Furthermore, stringent yet efficient regulatory pathways from bodies such as the Food and Drug Administration (FDA) in the United States support the swift approval and integration of innovative medical devices and therapies. This environment, combined with substantial investments in clinical trials and public health initiatives promoting cardiac care awareness, underpins North America's market dominance.

Recent Developments

• In November 2025, Archeon Medical, a firm focused on emergency ventilation monitoring, initiated three independent clinical investigations across the United States for its EOlife® ventilation feedback system. These studies were launched in Chicago, Portland, and St. Louis, aiming to validate the device's efficacy in enhancing cardiac arrest care. The EOlife® system provides real-time monitoring of manual ventilation quality, building on prior French field trial results that indicated improved survival rates and neurological outcomes for out-of-hospital cardiac arrest patients.
• In August 2025, Cardio Partners, Inc., a division of Sarnova, HC LLC, completed the acquisition of RescueStat, a healthcare technology company specializing in AED program management and remote monitoring. This acquisition significantly enhanced Cardio Partners' capabilities in delivering emergency readiness solutions. The strategic move aimed to strengthen the company's mission to increase survival rates from sudden cardiac arrest by expanding its service offerings and integrating RescueStat's two decades of expertise in AED program oversight and smart monitoring technology.
• In April 2025, Kestra Medical Technologies showcased its ASSURE® system at the Heart Rhythm 2025 annual meeting. This event marked the company's first major industry presentation following its successful initial public offering earlier in the year. The ASSURE system, a wearable cardioverter defibrillator, was highlighted for its innovation in providing protection and supporting recovery for patients at risk of sudden cardiac arrest. It integrates life-saving defibrillation therapy with advanced diagnostic and patient support features, contributing to a more comprehensive approach to cardiac care.
• In December 2024, Avive Solutions, Inc. and MedPro Associates announced a strategic three-year partnership to introduce Avive's next-generation connected automated external defibrillator (AED) technology. This collaboration aimed to integrate Avive's innovative AEDs into various medical settings, including primary, acute, post-acute, and ambulatory care centers nationwide. The initiative sought to leverage MedPro's extensive national sales network to enhance the availability of advanced AED technology, thereby improving preparedness and response capabilities for sudden cardiac arrest emergencies across the healthcare landscape.

Key Market Players

• Koninklijke Philips N.V
• Abbott Laboratories
• Medtronic plc
• Boston Scientific Corporation
• Novartis AG
• ZOLL Corporation
• Stryker
• Nihon Corporation
• BIOTRONIK
• GE Technologies

By Product (Value)	By End User (Value)	By Region
Devices Defibrillators Extracorporeal Membrane Oxygenation (ECMO) Intra-aortic Balloon Pump (IABP) Percutaneous VAD (Impella) Other Devices Drugs Anti-arrhythmic Drugs Class I – Sodium-channel Blockers Class II – Beta-blockers Class III – Potassium-channel Blockers Class IV – Calcium-channel Blockers||| Others (Digoxin, Adenosine) Vasopressors & Inotropes	Hospitals & Cardiac Centres Emergency Medical Services (EMS) Home & Alternate Care Settings	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Cardiac Arrest Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cardiac Arrest Treatment Market, By Product (Value):

• Devices
• Defibrillators
• Extracorporeal Membrane Oxygenation (ECMO)
• Intra-aortic Balloon Pump (IABP)
• Percutaneous VAD (Impella)
• Other Devices
• Drugs
• Anti-arrhythmic Drugs
• Class I – Sodium-channel Blockers
• Class II – Beta-blockers
• Class III – Potassium-channel Blockers
• Class IV – Calcium-channel Blockers|||
• Others (Digoxin, Adenosine)
• Vasopressors & Inotropes

• Cardiac Arrest Treatment Market, By End User (Value):

• Hospitals & Cardiac Centres
• Emergency Medical Services (EMS)
• Home & Alternate Care Settings

• Cardiac Arrest Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE